CALCIJEX (calcitriol) by AbbVie is clinical pharmacology man's natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin d 3 (cholecalciferol). Approved for secondary hyperparathyroidism, chronic kidney disease, psoriasis and 2 more indications. First approved in 1986.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
CALCIJEX (calcitriol) is an injectable active form of vitamin D3 that regulates calcium and phosphorus metabolism. It is indicated for secondary hyperparathyroidism in chronic kidney disease patients whose kidneys cannot adequately synthesize calcitriol. The drug works by binding to calcitriol receptors in the intestine and bone to stimulate calcium absorption and correct hypocalcemia.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team downsizing and shift toward generic defense strategies for the AbbVie portfolio.
CLINICAL PHARMACOLOGY Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Vitamin D 3 must be metabolically activated in the liver and the kidney before it is fully…
Worked on CALCIJEX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
Oral Calcitriol With Ketoconazole in CRPC
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
CALCIJEX offers stable but declining career prospects as a legacy injectable in the nephrology space. Professionals joining this team should expect focus on defensive commercial strategies, specialty channel optimization, and potential transition planning as generics enter.